Yohann Loriot discusses the TROPHY-U-01 trial update confirming that sacituzumab govitecan is active in heavily pretreated metastatic urothelial cancer (5:26).
This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany